source
- Ipsen's Dysport shows positive Phase 3 results in migraine, Tarsus acquires iRenix for $75MIpsen reported that its injectable neurotoxin Dysport met the primary endpoint in a Phase 3 trial aimed at reducing monthly migraine days. The trial demonstrated a statistically significant reduct…
- GSK terminates $700 million Alector partnership after recent trial setbacksGSK has decided to end its collaboration with Alector, a biotech focused on neurodegenerative diseases. The agreement originally included a $700 million upfront payment. The move follows two high-…